
|Videos|November 7, 2014
Using the LGR5 Protein as a Biomarker in Thyroid Cancer
Author(s)Brittany N. Bohinc, MD
Brittany N. Bohinc, MD, Division of Endocrinology, Duke University, discusses the potential to use LGR5 as a biomarker in papillary thyroid cancer.
Advertisement
Clinical Pearls
Brittany N. Bohinc, MD, Division of Endocrinology, Duke University, discusses the potential to use LGR5 as a biomarker in papillary thyroid cancer.
- LGR5 is a protein that marks cancer stems cells. It is known to be important in colorectal cancer and gastric cancer.
- Using two methods, researchers found that LGR5 was highly expressed in papillary thyroid cancer.
- LGR5 in thyroid cancer is associated with lymph node number, lymph node metastases, tumor size, T stage, N stage, extrathyroidal extension, lymphovascular invasion, and macroscopic extension.
- LGR5 could be used as a biomarker for novel therapeutics or risk stratification for surgery.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5



































